High early mortality rate in elderly patients with multiple myeloma receiving a vincristine-doxorubicin-dexamethasone regimen

American Journal of Hematology

Volumn 85, Issue 10, 2010, Pages 812-815

  Teng, Hao Wei ^a,b   Teng, Chung Jen ^a,b   Wang, Wei Shu ^b   Chen, Po Min ^a,b   Chiou, Tzeon Jye ^a,b   Hsu, Hui Chi ^b,c   Liu, Jin Hwang ^a,b   Yen, Chueh Chuan ^a,b   Hsiao, Liang Tsai ^a,b   Yang, Muh Hwa ^a,b   Chao, Ta Chung ^a,b   Yang, Ya Hsu ^c   Gau, Jyh Pyng ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISOLONE; VINCRISTINE; ANTINEOPLASTIC AGENT; PREDNISONE;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BLEEDING; CANCER STAGING; COMPARATIVE STUDY; COMPLICATION; FOLLOW UP; INCIDENCE; INFECTION; KIDNEY; KIDNEY DISEASE; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INCIDENCE; INFECTION; KIDNEY; KIDNEY DISEASES; MALE; MELPHALAN; MULTIPLE MYELOMA; NEOPLASM STAGING; PREDNISONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 77957675974     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21823     Document Type: Article

References (26)

1. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990;33:86-89. (Pubitemid 20040083)
2. Cavo M, Benni M, Ronconi S, et al. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: Final analysis of a randomized clinical study. Haematologica 2002;87:934-942.
3. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-1356. (Pubitemid 14149087)
4. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998;16:3832-3842.
5. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J Clin Oncol 1992;10:334-342.
6. Blade J, San Miguel J, Alcala A, et al. A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma. Blut 1990;60:319-322. (Pubitemid 20233347)
7. Lokhorst HM, Meuwissen OJ, Bast EJ, et al. VAD chemotherapy for refractory multiple myeloma. Br J Haematol 1989;71:25-30. (Pubitemid 19047692)
8. Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989;2:882-885. (Pubitemid 19245289)
9. Delain M, Linassier C, Petitdidier C, et al. VAD-PECC regimen in the treatment of advanced-stage multiple myeloma. J Clin Oncol 1994;12:2706-2713. (Pubitemid 24379660)
10. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680-1685.
11. Anderson H, Scarffe JH, Ranson M, et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995;71:326-330.
12. Segeren CM, Sonneveld P, van der Holt B, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999;105:127-130. (Pubitemid 29197154)
13. Monconduit M, Menard JF, Michaux JL, et al. VAD or VMBCP in severe multiple myeloma. The Groupe d'Etudes et de Recherche sur le Myelome (GERM). Br J Haematol 1992;80:199-204.
14. Sheehan T, Judge M, Parker AC. The efficacy and toxicity of VAD in the treatment of myeloma and related disorders. Scand J Haematol 1986;37:425-428.
15. Koskela K, Pelliniemi TT, Remes K. VAD regimen in the treatment of resistant multiple myeloma: slow or fast infusion? Leuk Lymphoma 1993;10:347-351.
16. Facon T, Mary JY, Pegourie B, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for highdose therapy. Blood 2006;107:1292-1298.
17. Ludwig H, Hajek R, Tothova E, et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009;113:3435-3442.
18. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006;91:1498-1505. (Pubitemid 44736116)
19. Harousseau JL. Thalidomide in multiple myeloma: Past, present and future. Future Oncol 2006;2:577-589. (Pubitemid 44575644)
20. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
21. Kenealy M, Prince HM. Current status of new drugs for the treatment of patients with multiple myeloma. Intern Med J 2006;36:781-789. (Pubitemid 44691186)
22. Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med 1980;302:1347-1349.
23. Kyle RA. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Eur J Haematol Suppl 1989;51:70-75. (Pubitemid 20118754)
24. Greipp PR, Kyle RA. Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. Blood 1983;62:166-171.
25. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.
26. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.